CDK8 and ovarian cancer: The present study reveals that targeting CDK8/19i can provide a strategy for potentiating the cytotoxic effects of existing chemotherapeutics used in OCCC treatment and proposes potent CDK8/19is as a viable option for further exploration and optimization in the treatment of ovarian cancers.